Search Results

You searched for : lilly  

Digital Health for Obesity Market Size Worth USD 466.53 Billion by 2034 | CAGR: 23.15%

Obesity management is entering a digital-first era. For decades, weight management has largely depended on periodic consultations, standardized diet plans, and patient self-reporting. ...
Aug 12

FICCI and Lilly launch the Bharat Life Sciences Awards to recognise India’s scientific excellence

Supported by the Office of the Principal Scientific Advisor to the Government of India, the Department of Pharmaceuticals, Biotechnology Industry Research Assistance Council, and Invest ...
Jun 03

Lilly launches Lormalzi® (Donanemab), first and only once-monthly amyloid plaque-targeting therapy for the treatment of early symptomatic Alzheimer’s Disease in India

Prescription only, limited duration dosing regimen guided by amyloid plaque removal....
May 14

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (8.9 kg ;9.2%) compared to 11.0 lbs (5 ...
Feb 28

Lilly’s New Obesity Awareness Campaign Seeks to Shift Obesity Discourse from Blame to Science and Empathy

Campaign blends lived experiences with science led perspectives to challenge obesity stigma and emphasise the importance of guidance from doctors....
Feb 28

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI

Very recently, two global giants, NVIDIA and Eli Lilly and Company had announced a first-of-its-kind AI co-innovation lab focused on applying ...
Feb 20

BioAsia 2026 to Convene the World’s Leading Science, AI, and Industry Pioneers Driving the TechBio Revolution

Global innovators shaping AI-native biology, next-generation medicines and digital-first healthcare to chart the future of global health....
Feb 05

A ₹100-Crore Question: Are GLP-1 Injections Becoming India’s New Lifeline?

The obesity epidemic is vast. The solutions are emerging. Science is evolving. And the market is expanding. The launch of Yurpeak is another step in ...
Dec 12

Lilly’s Donanemab Receives CDSCO Approval for the Treatment of Early Symptomatic Alzheimer’s Disease

Eli Lilly and Company (India) Pvt. Ltd. today announced that the Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization for donanemab for the ...
Nov 19

The Slimmer Price War: How Wegovy’s Price Slash Signals a New Era in India’s Weight-Loss Drug Market

As the patent clock ticks towards 2026, both Novo and Lilly are likely to intensify their efforts in expanding supply chains, boosting physician engagement, and ...
Nov 14

Lilly’s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ...
Oct 16

Lilly’s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ...
Oct 15

Lilly Announces Over $1 Billion Investment in New Contract Manufacturing in India

Investment to expand manufacturing and global medicine supply capacity — resonating with the Make in India agenda....
Oct 06

Lilly's oral GLP-1, Orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity

Participants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an average of 10.4 kg (10.5%) ...
Aug 28

Credibility Meets Convenience: India’s GLP-1 Battleground Gets a KwikPen Revolution

Long-term effects of GLP-1 medications remain under investigation, and shifting to easy-to-use pens removes barriers but not risks....
Aug 16

Lilly Expands India Presence with Inauguration of Hyderabad Site to Accelerate Global Digital Innovation

Hyderabad site will support innovation and strengthen digital capabilities across Lilly’s global operations....
Aug 04

Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease

Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C ...
Aug 01

Wegovy Lands in India: Miracle Weight Loss Shot or Medical Marketing Hype?

As India confronts an alarming rise in obesity and related conditions like type 2 diabetes, cardiovascular disease, and polycystic ovarian syndrome, the spotlight on medical ...
Jun 25

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year....
Jun 23

Lilly, Apollo Health and Lifestyle and Apollo HealthCo Ltd. partner to drive nationwide awareness on obesity and type 2 diabetes

Eli Lilly and Company (India) has entered into a partnership with Apollo Clinic, a prominent clinic network under Apollo Health and Lifestyle, and Apollo HealthCo. ...
May 29

Mounjaro (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

...
May 12

Lilly Launches Mounjaro® (tirzepatide), offering a new option for the treatment of obesity and type 2 diabetes

...
Mar 20

Lilly India appoints Winselow Tucker as the President and General Manager

Winselow holds a bachelor’s degree in business administration from Howard University and a Master of Business Administration from Indiana University....
Feb 04

From Dependence to Dominance: Lupin’s Leap in the Diabetes Market

With a focus on affordability, accessibility, and innovation, Lupin is leading the way for better diabetes management and improved quality of life for patients....
Jan 03

Is Your Lifestyle Putting You at Risk for Dementia? Discover the Hidden Dangers

While the quest for a cure for dementia continues, the potential for prevention through addressing risk factors offers hope....
Aug 03

25 Matching result(s) found!

-Advertisements-



Trending Now

Vahan.ai Advances Multilingual AI Recruitment with NVIDIA NemotronAugust 25, 2026
Vahan.ai Advances Multilingual AI Recruitment with NVIDIA NemotronAugust 25, 2026
Beyond Basic Baby Care: Addressing the Monsoon Surge in Infant Skin Concerns with Salve’s Littloo RangeAugust 25, 2026
100+ Bengaluru Clinics Use QR678® as Indian Hair Regeneration Platform Adds New Patent and Expands GloballyAugust 25, 2026
Healthcare Innovation in India: Real Stories That Are Reshaping the Future of MedicineAugust 25, 2026
Generative AI in Indian Hospitals: Where It Is Actually Making a Difference in 2026August 25, 2026
High Uric Acid and Gout: Symptoms, Causes, Diet, Tests, and Treatment ExplainedAugust 24, 2026
Vitamin D Deficiency in India: Symptoms, Causes, Tests, Treatment and PreventionAugust 24, 2026
SRM College of Pharmacy Hosts Two-Day National Pharmaceutical ConferenceAugust 21, 2026
Atomy India Joins Hands with the Paralympic Committee of India as OfficialNutrition and Wellness PartnerAugust 21, 2026
Thumbay International Pathway - MD Program with Installments and a Direct Route to Residency in RomaniaAugust 21, 2026
THIP wins ‘Breakthrough Digital Patient Education Initiative’ award at India Vaccine Leaders Conclave in PuneAugust 21, 2026
Three Watermelons, a Mannequin Head and a PS5: What India Left Behind on Intercity BusesAugust 21, 2026
Evaluating Thyroid Nodules: Fine Needle Aspiration Cytology (FNAC) and Bethesda ClassificationAugust 21, 2026
Clinical Approaches to Acute Kidney Injury (AKI): Biomarkers, Staging, and Renal Replacement TherapyAugust 21, 2026
Diabetes Care in India: Understanding the Crisis, Bridging the Gaps, and Building a Healthier FutureAugust 21, 2026
Diabetes Management: Lifestyle Changes That Make a Real DifferenceAugust 21, 2026
TagMango introduces New AI capabilities for creator businesses at RISE 2026August 20, 2026
AFib: The Irregular Heartbeat We Need to Stop IgnoringAugust 20, 2026
Nanavati Max Launches Dedicated Cancer Helpline to Support Patients and Families In Their Cancer JourneyAugust 20, 2026